IMV Inc IMV-CA:Toronto Stock Exchange

*Data is delayed | CAD
Last | 09/23/22 EDT
0.77UNCH (UNCH)
52 week range
0.60 - 2.40
Loading...
  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close0.77
  • 52 Week High2.40
  • 52 Week High Date11/18/21
  • 52 Week Low0.60
  • 52 Week Low Date08/02/22

Key Stats

  • Market Cap46.72M
  • Shares Out82.22M
  • 10 Day Average Volume54,024.2
  • Dividend-
  • Dividend Yield-
  • Beta2
  • YTD % Change-50.64

KEY STATS

  • Open0.00
  • Day High0.00
  • Day Low0.00
  • Prev Close0.77
  • 52 Week High2.40
  • 52 Week High Date11/18/21
  • 52 Week Low0.60
  • 52 Week Low Date08/02/22
  • Market Cap46.72M
  • Shares Out82.22M
  • 10 Day Average Volume54,024.2
  • Dividend-
  • Dividend Yield-
  • Beta2
  • YTD % Change-50.64

RATIOS/PROFITABILITY

  • EPS (TTM)-0.67
  • P/E (TTM)-1.14
  • Fwd P/E (NTM)-
  • EBITDA (TTM)-
  • ROE (TTM)-
  • Revenue (TTM)-
  • Gross Margin (TTM)-
  • Net Margin (TTM)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On IMV Inc

 

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
IMV Inc. is a clinical-stage immuno-oncology company. The Company is focused on developing a portfolio of therapies based on DPX, an immune-educating technology platform, that is designed to inform a specific anti-tumor immune response, offering benefit to patients with solid or hematological cancers. Its lead candidate, maveropepimut-S (MVP-S) is a DPX-based immunotherapy that targets survivin-expressing cells for elimination by educated, cytotoxic T cells. Its other...
Michael Bailey
Independent Chairman of the Board
Andrew Hall
Chief Executive Officer, Director
Address
130 Eileen Stubbs Ave Suite 19
Dartmouth, NS
B3B 2C4
Canada

Top Peers

SYMBOLLASTCHG%CHG
MDNA
Medicenna Therapeutics Corp
0.8305-0.025-2.9223%
APS
PMN
ProMIS Neurosciences Inc
5.58+0.50+9.82%
SBM
DMAC
DiaMedica Therapeutics Inc
1.22-0.14-10.29%